388 completed, 119 unknown, 95 recruiting, 85 terminated. 802 Phase 3, 131 Phase 2.
Follow Leukemia: new trials by email Literature Review of Leukemia trials Research Report on Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study Evaluating Subcutaneous Versus Intravenous Blinatumomab in Newly Diagnosed Adults With B-cell Precursor Acute Lymphoblastic Leukaemia Blinatumomab, HyperCVAD - Philadelphia Chromosome Negative B-cell Precursor Acute Lymphoblastic Leukemia | Phase 3 | Not yet recruiting | Amgen | 560 | 2028-06-30 | 2026-09-15 |
| Methadone as an Alternative Treatment for Children Underdoing HSCT PCA plus methadone (Experimental), PCA Alone (SOC) - Leukemia, Aplastic Anemia | Phase 3 | Suspended | University of Texas Southwestern Medical Center | 60 | 2028-01-01 | 2025-10-23 |
| A Randomized Study of ELVN-001 Versus Investigator-Selected TKI, in CP-CML Previously Treated With One or More TKIs ELVN-001, TKI - Chronic Myeloid Leukemia (CML), Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive | Phase 3 | Not yet recruiting | Enliven Therapeutics | 450 | 2026-12-31 | 2026-10-29 |
| FLT3-ITD Targeted Therapy in Fit AML Patients Gilteritinib, Venetoclax, Azacitidine (AZA) - AML (Acute Myeloid Leukemia) | Phase 2 / Phase 3 | Not yet recruiting | European Organisation for Research and Treatment of Cancer - EORTC | 230 | 2026-12-01 | 2026-02-23 |
| A Study of HS-10382 Versus Investigator-selected TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP HS-10382, Imatinib, Dasatinib - Chronic Myeloid Leukemia | Phase 3 | Not yet recruiting | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 408 | 2026-12-01 | 2026-10-21 |
| A Study to Assess How Well the Study Medicine IPN60340 Works in Combination With Azacitidine and Venetoclax, Compared to Placebo in Combination With Azacitidine and Venetoclax, in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Cannot Receive Intensive Chemotherapy IPN60340 + azacitidine + venetoclax, Placebo + azacitidine + venetoclax - Acute Myeloid Leukaemia (AML), Acute Myeloid Leukaemia | Phase 2 / Phase 3 | Not yet recruiting | Ipsen | 540 | 2026-11-01 | 2026-09-10 |
| A Phase III Study Comparing Mesutoclax + Azacitidine Versus Venetoclax + Azacitidine in Untreated Acute Myeloid Leukemia (AML) Patients Mesutoclax (ICP-248), Azacitidine (AZA), Venetoclax - Acute Myeloblastic Leukaemia | Phase 3 | Not yet recruiting | Beijing InnoCare Pharma Tech Co., Ltd. | 318 | 2026-11-01 | 2026-11-09 |
| Umbilical Cord Blood Consolidation for Older Adults With Intermediate- and High-Risk AML Unrelated Umbilical Cord Blood Infusion, Standard consolidation chemotherapy with high-dose cytarabine - AML (Acute Myelogenous Leukemia) | Phase 3 | Not yet recruiting | Shanghai Jiao Tong University School of Medicine | 132 | 2026-10-01 | 2026-08-12 |
| Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies IgPro20 - Secondary Immune Deficiency | Phase 3 | Recruiting | CSL Behring | 63 | 2026-09-15 | 2026-10-14 |
| Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL) Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration - Stage II T Lymphoblastic Leukemia/Lymphoma, Stage III T Lymphoblastic Leukemia/Lymphoma | Phase 2 / Phase 3 | Not yet recruiting | Children's Oncology Group | 1708 | 2026-08-28 | 2026-07-30 |
| Chidamide Maintenance to Prevent Relapse After Allogeneic Hematopoietic Stem Cell Transplantation in Acute T-Lymphoblastic Leukemia/Lymphoma Chidamide, Control Group - T-Cell Acute Lymphoblastic Leukemia, T-Cell Lymphoblastic Lymphoma | Phase 3 | Not yet recruiting | First Affiliated Hospital of Zhejiang University | 132 | 2026-08-15 | 2026-08-19 |
| Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia Best Practice, Biospecimen Collection, Cytarabine - Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia | Phase 3 | Recruiting | Children's Oncology Group | 556 | 2026-08-14 | 2026-09-04 |
| Lisaftoclax Plus Azacitidine Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia Patients at High Risk of Relapse Lisaftoclax Plus Azacitidine - Acute Myeloid Leukemia (AML), Maintenance Treatment | Phase 3 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 191 | 2026-08-10 | 2026-07-07 |
| A Study of Injectable BLB101 and Blincyto® in Adult Participants With R/R CD19+ B-ALL BLB101 for Injection, Blinatumomab for Injection - Precursor B-cell Acute Lymphoblastic Leukemia | Phase 3 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 212 | 2026-08-09 | 2026-07-23 |
| Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL NX-5948, Pirtobrutinib - B-cell Lymphoma, Chronic Lymphocytic Leukemia | Phase 3 | Recruiting | Nurix Therapeutics, Inc. | 620 | 2026-08-03 | 2026-08-31 |
| A Clinical Trial to Evaluate the Efficacy and Safety of TQB3909 Tablets Versus Investigator's Choice in the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) TQB3909 Tablets, Bendamustine Injection, Rituximab injection - Small Lymphocytic Lymppho, Relapsed/Refractory Chronic Lymphocytic Leukemia | Phase 3 | Not yet recruiting | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 128 | 2026-08-01 | 2026-08-11 |
| Mitoxantrone Hydrochloride Liposome, Cytarabine, G-CSF Plus Venetoclax vs. Azacitidine Plus Venetoclax for MDS-IB2 and Secondary/Elderly AML Mitoxantrone Hydrochloride Liposome, Cytarabine, Granulocyte Colony-Stimulating Factor(G-CSF) - Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) | Phase 3 | Not yet recruiting | Ruijin Hospital | 168 | 2026-07-30 | 2026-07-29 |
| Azacytidine, Venetoclax Plus Minus Quizartinib for First Line Older/Unfit AML Patients (VENP-A-QUI) Azacitidine, Venetoclax, Quizartinib - Acute Myeloid Leukemia, Adult | Phase 3 | Recruiting | PETHEMA Foundation | 376 | 2026-07-02 | 2026-11-04 |
| Personalising Treatment for Myeloma Patients Based on Initial Response to NHS Treatment and Their Overall Fitness Level Daratumumab, Lenalidomide, Dexamethasone - Multiple Myeloma (MM), Plasma Cell Leukemia (PCL) | Phase 3 | Recruiting | University of Leeds | 1226 | 2026-07-01 | 2026-07-15 |
| Lisaftoclax for Prevention of Differentiation Syndrom in Acute Promyelocytic Leukemia Patients Lisaftoclax (APG-2575) - Acute Promyelocytic Leukemia (APL) | Phase 2 / Phase 3 | Not yet recruiting | The Affiliated People's Hospital of Ningbo University | 20 | 2026-07-01 | 2026-06-30 |
Showing 20 of 802. Sign in to see all of them.
Leukemia, Myeloid, Acute (330) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (198) · Leukemia, Lymphocytic, Chronic, B-Cell (176) · Myelodysplastic Syndromes (101) · Lymphoma (94) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (85) · Lymphoma, Non-Hodgkin (71) · Leukemia, Myeloid, Chronic-Phase (58) · Lymphoma, Follicular (57) · Burkitt Lymphoma (56) · Lymphoma, Large B-Cell, Diffuse (50) · Lymphoma, B-Cell, Marginal Zone (48) · Lymphoma, Mantle-Cell (48) · Multiple Myeloma (47)
Hemic and Lymphatic Diseases (802) · Neoplasms by Histologic Type (799) · Hematologic Diseases (788) · Neoplasms (761) · Leukemia, Myeloid (444) · Immune System Diseases (407) · Immunoproliferative Disorders (398) · Lymphatic Diseases (397) · Lymphoproliferative Disorders (390) · Leukemia, Lymphoid (360) · Pathological Conditions, Signs and Symptoms (336) · Pathologic Processes (330) · Disease Attributes (315) · Chronic Disease (299)
Cytarabine (192) · Cyclophosphamide (129) · Daunorubicin (102) · Methotrexate (96) · Etoposide (77) · Vincristine (72) · venetoclax (69) · Dexamethasone (66) · Azacitidine (61) · Mercaptopurine (61) · Rituximab (56) · fludarabine (55) · Idarubicin (53) · Doxorubicin (51) · Asparaginase (49)
Children's Oncology Group (36) · Novartis Pharmaceuticals (29) · National Cancer Institute (NCI) (22) · European Organisation for Research and Treatment of Cancer - EORTC (21) · The First Affiliated Hospital of Soochow University (21) · Nanfang Hospital, Southern Medical University (17) · M.D. Anderson Cancer Center (15) · Hoffmann-La Roche (13) · AbbVie (12) · German CLL Study Group (12) · Gilead Sciences (12) · St. Jude Children's Research Hospital (12) · Institute of Hematology & Blood Diseases Hospital, China (11) · Assistance Publique - Hôpitaux de Paris (10) · Alliance for Clinical Trials in Oncology (9)
United States (355) · Germany (211) · France (203) · Italy (175) · Canada (169) · Australia (159) · United Kingdom (156) · Spain (154) · China (152) · Belgium (132) · Czechia (114) · Poland (114) · Austria (107) · Netherlands (93) · Israel (92)
Michael Hallek, MD (7) · Qifa Liu (7) · Mary Horowitz, MD (4) · Xiaofan Zhu, MD (4)
PMID 33242441, PMID 38620092, PMID 39121442, PMID 35829925, PMID 37267439, PMID 37341189, PMID 40266025, PMID 22965967, PMID 23007406, PMID 24970932, PMID 28751558, PMID 31196847, PMID 31375516, PMID 33131249, PMID 34865212, PMID 36184192, PMID 36815378, PMID 37890117, PMID 38295280, PMID 38446568, PMID 41671463, PMID 42085603, PMID 15812540, PMID 19602710, PMID 20154213, PMID 20625116, PMID 21195303, PMID 21343560, PMID 21459791, PMID 21719599, PMID 22649106, PMID 23233662, PMID 23248249, PMID 23515925, PMID 23620574, PMID 23749683, PMID 23841729, PMID 24344215, PMID 24797299, PMID 24816240, PMID 24859364, PMID 24916506, PMID 25103870, PMID 25753432, PMID 25987659, PMID 26590194, PMID 26888258, PMID 26913693, PMID 28273028, PMID 29148893
U10CA098543 (16), 2023 (13), 2025 (12), U10CA180886 (12), 2015 (11), 2014 (10), 2016 (9), U10CA021115 (9), 2017 (8), 2009 (6), 2018 (6), U10CA031946 (6), UG1CA189955 (6), 2008 (5), U01HL069294 (5)